SCHEMBL1908597

SCHEMBL1908597

c1cc2cc(-c3ccc(OC4CCN5CCC[C@@H]4C5)nn3)ccc2[nH]1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 13/20 0.77
CHRNB2 P17787 8/20 0.51
CHRNA4 P43681 8/20 0.51
CHRNB4 P30926 7/20 0.51
CHRNA3 P32297 7/20 0.51
HTR3A P46098 1/20 0.50
KCNH2 Q12809 4/20 0.42
CYP17A1 P05093 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
CHRNA10 Q9GZZ6 1/20 0.35
CHRNA9 Q9UGM1 1/20 0.35
DYRK3 O43781 1/20 0.34
CCNT1 O60563 1/20 0.34
CDK9 P50750 1/20 0.34
CDK5 Q00535 1/20 0.34
DYRK1A Q13627 1/20 0.34
CDK5R1 Q15078 1/20 0.34
DYRK2 Q92630 1/20 0.34
DYRK1B Q9Y463 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1146251 1.00 CHRNA7 (0.77) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL1146254 1.00 CHRNA7 (0.77) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL415245 1.00 CHRNA7 (0.77) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
Methane SCHEMBL17004210 0.99 CHRNA7 (0.76) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
Abt-107 SCHEMBL29364159 0.87 CHRNA7 (1.00) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
Abt-107 SCHEMBL373047 0.87 CHRNA7 (1.00) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
Abt-107 SCHEMBL527745 0.87 CHRNA7 (1.00) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
Abt-107 SCHEMBL1542259 0.87 CHRNA7 (1.00) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
Abt-107 SCHEMBL31393053 0.87 CHRNA7 (1.00) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL1908561 0.86 CHRNA7 (0.57) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022074-A1 ORGANIC COMPOUNDS NOVARTIS AG 2012-01-26 US disclosed
US-20120022074-A1 ORGANIC COMPOUNDS NOVARTIS AG 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022074-A1 ORGANIC COMPOUNDS TPMT, DNMT1, DNMT3L CHRNA7 254/4885CHRNB2 977/4885CHRNA4 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.